Real-world incidence and risk factors of bortezomib-related cardiovascular adverse events in patients with multiple myeloma
CONCLUSION: Approximately 15% of the Korean patients treated with bortezomib experienced severe CVAEs. Thus, patients, especially those with identified risk factors, should be closely monitored for CVAE symptoms during bortezomib treatment.PMID:38485811 | PMC:PMC10903519 | DOI:10.1007/s44313-024-00004-y
Source: Blood Research - Category: Hematology Authors: Bitna Jang Jonghyun Jeong Kyu-Nam Heo Youngil Koh Ju-Yeun Lee Source Type: research
More News: Arrhythmia | Cardiology | Cardiovascular | Heart | Heart Attack | Heart Failure | Hematology | Hypertension | Myeloma | Pulmonary Thromboembolism | South Korea Health | Stroke | Study | Thrombosis | Toxicology | Velcade